C3L-02130
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 70.92950034
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12475169 | — | — | 0.846 |
| 2 | SRR8943009 | — | — | 0.839 |
| 3 | SRR8526723 | — | cohortA1 | 0.815 |
| 4 | TCGA-C8-A135-01A-11R-A115-07 | — | C | 0.806 |
| 5 | TCGA-52-7811-01A-11R-2125-07 | — | cohortSQ1 | 0.803 |
| 6 | TCGA-34-5236-01A-21R-1820-07 | — | cohortSQ1 | 0.802 |
| 7 | 6a8cad2e-350a-4c0b-9680-41d83ef1eb5d | — | — | 0.799 |
| 8 | MNG1297 | — | — | 0.795 |
| 9 | TCGA-68-7756-01A-11R-2125-07 | — | cohortSQ1 | 0.790 |
| 10 | TCGA-CR-5247-01A-01R-2016-07 | — | — | 0.782 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.560 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.400 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| HYPOXIA | 0.330 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.320 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.310 | Inavolisib | — uncovered |
| MYOGENESIS | 0.310 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.290 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.270 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.260 | Inavolisib | — uncovered |
| APOPTOSIS | 0.260 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.260 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.210 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.210 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.210 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |